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Protocol
AbstrACt
Introduction Post-traumatic stress disorder (PTSD) is 
common among children and adolescents who are exposed 
to trauma, and it is often associated with significant negative 
impacts on their psychosocial functioning and quality of 
life. Many types of psychotherapies have been found to be 
effective for PTSD in children and adolescents. However, 
due to the lack of direct comparisons between different 
psychotherapies, the hierarchy of treatment efficacy is still 
unclear. Therefore, we plan to conduct a systematic review 
and network meta-analysis to evaluate the efficacy and 
acceptability of various types of psychotherapies for PTSD in 
children and adolescents.
Methods and analysis A systematic search will be 
conducted among eight electronic databases, including 
PubMed, Cochrane, Embase, Web of Science, PsycINFO, 
Cumulative Index of Nursing and Allied Health, Published 
International Literature on Traumatic Stress (PILOTS) and 
ProQuest Dissertations, from inception to October 2017. 
Randomised controlled trials, regardless of language, 
publication year and publication type, comparing any 
psychotherapies for PTSD to any control condition or 
alternative treatment in children and adolescents (18 years 
old or less) diagnosed with full or subclinical PTSD will 
be included. Study duration and the number of treatment 
sessions will not be limited. The primary outcome will be 
PTSD symptom severity at post-treatment as measured by 
a rating scale reported by the child, parent or a clinician. The 
secondary outcomes will include: (1) efficacy at follow-up; (2) 
acceptability (all-cause discontinuation); (3) anxiety symptom 
severity; (4) depressive symptom severity and (5) quality of 
life and functional improvement. Bayesian network meta-
analyses for all relative outcome measures will be performed. 
We will conduct subgroup and sensitivity network meta-
analyses to determine whether the findings are affected by 
study characteristics. The quality of the evidence contributing 
to network estimates of the primary outcome will be 
evaluated by the Grading of Recommendations, Assessment, 
Development and Evaluations framework.
Ethics and dissemination No ethical issues are foreseen. 
The results will be published in a peer-reviewed journal, 
which will be disseminated electronically and in print. This 
network meta-analysis may be updated to inform and 
guide the clinical management of PTSD in children and 
adolescents.
PrOsPErO registration number CRD42016051786.
bACkgrOund 
Many children and adolescents are exposed 
to trauma, with more than two-thirds 
strengths and limitations of this study
 ► Bayesian network meta-analysis can simultaneously 
compare various types of treatments by integrating 
all the best evidence (direct and indirect evidence) to 
estimate the interrelations across all treatments and 
establish a treatment hierarchy for psychotherapies 
for post-traumatic stress disorder (PTSD) in children 
and adolescents.
 ► A number of outcomes will be used to 
comprehensively assess efficacy at post-treatment 
and follow-up, acceptability, anxiety and depressive 
symptom severity, quality of life and functional 
improvement.
 ► This study will help to guide clinical decision-making 
regarding the relative efficacy of various types of 
psychotherapy and various delivery modalities in 
the treatment of PTSD in children and adolescents.
 ► Subgroup and sensitivity network meta-analyses 
will help to find potential moderators that affect the 
efficacy of psychotherapies.
 ► The limitations of included studies will be assessed 
using the Cochrane Collaboration’s risk of bias 
V.2.0 tool, and the quality of evidence for network 
estimates of the primary outcome will be evaluated 
by the Grading  of Recommendations, Assessment, 
Development and Evaluations framework.
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reporting at least one traumatic event by 16 years of 
age.1 Post-traumatic stress disorder (PTSD) is one of the 
most common mental disorders among children and 
adolescents who have experienced trauma. Data from 
a meta-analysis pooling 72 articles with 3563 trauma-ex-
posed children and adolescents show that the overall 
rate of PTSD was 15.9%.2 As described in the Diagnostic 
and Statistical Manual of Mental Disorders, Fifth edition 
(DSM-5), PTSD diagnostic criteria includes four symptom 
clusters: (1) re-experiencing of the traumatic event; (2) 
avoidance of stimuli associated with the traumatic event; 
(3) negative alterations in cognition and mood and (4) 
hyperarousal.3 Trauma exposure is an essential factor to 
be able to diagnose PTSD, which can include physical 
or sexual abuse, war or terrorism, natural or man-made 
disasters, witnessing domestic violence, catastrophic 
illnesses, vehicle or other accidents.4 5 PTSD is correlated 
with various adverse consequences for children and 
adolescents in cognitive, emotional, social, academic and 
other functional domains.6 In addition, PTSD commonly 
co-occurs with other psychiatric conditions, such as major 
depressive disorder,7 anxiety disorder,7 substance abuse8 
and attention deficit hyperactivity disorder (ADHD).9 
PTSD diagnosis is accompanied by a significant reduction 
in quality of life, and it is estimated that successful treat-
ment could save 2.05 quality adjusted life years per child 
or adolescent with PTSD.10 
Several forms of interventions have been applied to 
address PTSD symptoms in children and adolescents, 
from which psychotherapy is the mainstay of treatment.11 
Although some medications (eg, fluoxetine, paroxetine 
and venlafaxine) have shown a significant but small supe-
riority over placebo (mean effect size=0.23) in PTSD treat-
ment for adults,12 their use in children and adolescents is 
still limited because (1) the evidence of the effectiveness 
of pharmacological treatments for children and adoles-
cents with PTSD is scant13 and (2) medications have been 
associated with safety concerns in children and adoles-
cents, including evidence of increased risk of suicidality 
in children and adolescents treated with antidepres-
sants.14 15 Therefore, clinical guidelines recommend that 
psychotherapy should be used for the initial treatment of 
PTSD in children and adolescents.16
Since the 1990s, psychotherapies have been increasingly 
applied in the treatment of PTSD in children and adoles-
cents, and recent reviews have reported encouraging 
results on their efficacy.17–19 Evidence from Cochrane 
reviews found that psychological therapies are effective in 
preventing PTSD in children and adolescents who have 
undergone trauma and effective in treating PTSD in chil-
dren and adolescents.17 18 Many types of psychotherapies 
are now available, such as cognitive behavioural therapy 
(CBT), eye movement desensitisation and reprocessing 
(EMDR), behavioural therapy (BT), cognitive therapy, 
psychodynamic therapy and play therapy. Among these, 
trauma-focused CBT (TF-CBT), a CBT programme that 
uses cognitive-behavioural techniques with a trauma-fo-
cused component, is the most commonly practised 
psychotherapy for children and adolescents with PTSD.20 
TF-CBT has been recommended as a first-line treatment 
by clinical guidelines for PTSD in children and adoles-
cents.16 21 However, trauma-focused therapy can be diffi-
cult for some therapists to implement,22 23 and there 
are some safety concerns in clinical practice (eg, symp-
toms worsening and patients ending treatment prema-
turely).24 25 Two recent trials that directly compared 
TF-CBT with non-TF-CBT alternatives reported that both 
were efficacious.23 26 Thus, whether the inclusion of a 
trauma-focused component is essential in CBT for PTSD 
in children and adolescents is still uncertain. Moreover, 
other therapies, such as EMDR and BT, have also been 
reported effective in treating PTSD symptoms in children 
and adolescents.27 28 However, due to methodological 
limitations, conventional meta-analyses cannot simulta-
neously compare all these treatments. Therefore, they 
cannot provide a clear answer regarding the best choice 
for initial treatment nor can they provide a hierarchy of 
these psychotherapies.
Network meta-analysis is a newly developed method 
for evidence synthesis, which is able to integrate direct 
evidence (from studies directly comparing interven-
tions) with indirect evidence (derived from separate 
studies addressing a common reference condition) from 
multiple treatment comparisons to estimate the inter-
relations across all treatments.29 This approach enables 
a simultaneous comparison of multiple treatments and 
can provide hierarchical evidence to guide clinical 
practice. Using this method, our group has produced 
meta-analyses comparing the effects of different psycho-
therapies for the treatment of anxiety disorder30 and 
depressive disorder31 in children and adolescents. In 
the present study, we describe the methods to undertake 
a network meta-analysis to complement those previous 
reports that will focus on the efficacy of psychotherapies 
for children and adolescents with PTSD. By performing 
a well-designed Bayesian network meta-analysis, we aim 
to provide a higher level of evidence that can inform 
clinical guidelines for PTSD treatment in children and 
adolescents.
MEthOds
Criteria for included studies
Types of studies
All randomised controlled trials (RCTs), including 
cluster-randomised trials and cross-over trials, will be 
included. However, only the results from the first rando-
misation period will be considered in the cross-over trials. 
For the purpose of reducing heterogeneity between trials, 
we will exclude quasirandomised trials (eg, allocation 
based on the last number of the date of birth) and trials 
in which the sample size is less than 10 per study. Study 
duration and the number of treatment sessions will not 
be limited.
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Types of participants
Studies that enrolled children and adolescents, aged 18 
years old or less when they were initially enrolled, will be 
included in this review. Given that children with significant 
PTSD symptoms who do not meet full criteria for a PTSD 
diagnosis often have comparable functional impairment 
to those with a PTSD diagnosis,32–34 the clinical guideline 
suggested that treatment decisions should be based on 
symptom severity and functional impairment rather than 
whether or not they have an actual PTSD diagnosis.16 
Therefore, we will apply the following broad criteria to 
identify the participants: (1) Full PTSD, as diagnosed 
according to standardised diagnostic interviews based on 
international classifications (DSM,3 35–38 the International 
Classification of Diseases (ICD)39 40 or validated scales 
for PTSD based on DSM/ICD criteria)41–44; (2) subclin-
ical/partial PTSD, defined as patients who have experi-
enced psychological trauma and report some subsequent 
PTSD symptoms in at least one of the four symptom 
clusters according to DSM-5 (ie, re-experiencing, avoid-
ance, hyperarousal, negative alterations in cognition and 
mood)45; (3) clinically significant post-traumatic stress 
symptoms, defined as scoring above a validated cut-off 
on a PTSD rating scale, such as the Kiddie Schedule for 
Affective Disorders and Schizophrenia,42 Child PTSD 
Symptoms Scale46 and the Impact of Event Scale.47 We 
will include trials in which participants have a secondary 
diagnosis of comorbid general psychiatric disorders, 
for example, depressive disorder, anxiety disorder, 
ADHD and oppositional defiant disorder. However, 
trials in which participants have a diagnosis of acute 
stress disorder or adjustment disorder will be excluded. 
Studies where both adults and children/adolescents are 
included will be eligible for inclusion if the data for the 
latter can be obtained separately. Studies where it is not 
clear what happened to the patients who withdrew from 
the study will not be excluded, and all these patients will 
be counted as all-cause discontinuation. Trials conducted 
in any treatment settings, including outpatient clinics, 
inpatient services, community clinics and schools will be 
included.
Types of interventions
All RCTs comparing any psychotherapy against another 
psychotherapy or any control condition for children and 
adolescents with PTSD will be included. We will view each 
of: TF-CBT, non-trauma-focused CBT (non-TF-CBT), 
EMDR, BT, cognitive therapy, psychodynamic therapy, 
play therapy, and any other psychotherapy as independent 
nodes in this network meta-analysis. Trials comparing the 
same type of psychotherapies, but at different delivery 
conditions (with or without family involvement), different 
delivery formats (group, individual or group plus indi-
vidual) and different delivery mediums (face-to-face, 
internet-based) will be considered as the same node in 
this network meta-analysis. Nevertheless, because TF-CBT 
is the most commonly studied psychotherapy and recom-
mended by clinical guidelines as first-line choice for 
children and adolescents with PTSD,16 21 if data available, 
we will separate TF-CBT with different delivery condi-
tions, formats and mediums as independent nodes.
Control conditions can include waitlist, non-treat-
ment and treatment as usual. We will view each of these 
control conditions as independent nodes in this network 
meta-analysis. The detailed description of each treatment 
and control condition are presented in table 1. According 
to the principles described in this table, two reviewers will 
independently perform the classification of all conditions 
in each trial. Any disagreements will be discussed among 
the review team, and any unclear information will be 
requested from the relevant authors.
Studies where psychotherapy is used as a combination 
strategy (eg, combining psychotherapy with medication) 
will be excluded, because such designs make it impossible 
for us to estimate the effect size of each specific treat-
ment approach. We will not exclude studies that enrolled 
patients who had used medications in the past, provided 
that their medication status was not changed for at least 
1 month prior to study entry and for the study period.
Types of outcome measures
Primary outcome
1. Efficacy at post-treatment, as measured using the end-
point score from PTSD symptom severity rating scales 
completed by the child, parent or a clinician.48 When 
end-point scores are not reported, we will use change 
scores (if available).49 Where more than one scale is 
reported in a trial, we will extract data from the PTSD 
symptom scales on a hierarchy, which is based on psy-
chometric properties and appropriateness for use 
with children and adolescents (table 2). In addition, 
where a PTSD symptom scale is reported by different 
raters in a trial, self-rated outcome will be preferred, 
then the parent or clinician rated outcome, because 
self-rated outcome tends to result in more conserva-
tive effect sizes.50 Where dichotomous efficacy out-
comes, instead of continuous scores, are reported in 
a trial, we will contact the relevant authors to request 
the data we need. If they did not respond the data will 
not be used.
Secondary outcomes
1. Efficacy at follow-up, as measured by the score from 
PTSD scales at the longest point of follow-up (up to 12 
months). The selection priority of PTSD scales will be 
the same as for efficacy at post-treatment. Data from 
participants who take part in subsequent treatments 
(eg, continuing psychotherapy/pharmacotherapy or 
booster sessions) will be excluded in the follow-up 
analysis.
2. Acceptability, defined as all-cause discontinuation, as 
measured by the proportion of patients who discon-
tinued treatment for any cause at the end of treat-
ment. Notably, children and adolescents may discon-
tinue treatment for many different reasons, such as 
finding it difficult to adhere to long-term treatment, 
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because symptoms worsen, or due to rapid improve-
ment of symptoms.30
3. Anxiety symptoms, as measured by the end-point 
score on anxiety symptom severity rating scales. The 
following scales will be used: Revised Children’s Man-
ifest Anxiety Scale, Spence Children’s Anxiety Scale, 
Multidimensional Anxiety Scale for Children, State-
Trait Anxiety Inventory for Children, Screen for Anxi-
ety and Related Disorders. If none of above scales are 
reported, other valid anxiety scales will be used. When 
a scale is reported by different raters in a trial, self-rat-
ed outcome will be preferred.
4. Depressive symptoms, as measured by the end-point 
score on depressive symptom severity rating scales. 
The following scales will used: Children’s Depres-
sion Inventory, Beck depression inventory, Mood and 
Feeling Questionnaire, Children’s Depression Rating 
Scale Revised, Hamilton Depression Rating Scale. As 
for anxiety, other valid depression scales will be used 
if none of the above scales were reported.
5. Quality of life and functional improvement (QoL/
functioning). If data are available, we will extract 
continuous outcomes from scales of QoLand func-
tional improvement measured at post-treatment. The 
Table 1 Description of psychotherapeutic interventions and control condition
Interventions Abbreviation Description
Psychotherapeutic intervention
Trauma-focused 
cognitive behavioural therapy
TF-CBT CBT is a combination of cognitive and behavioural techniques. It also involves 
additional techniques such as relaxation training, affective modulation skills and 
enhancement of future safety and development. TF-CBT is a CBT programme 
that involves a trauma focus, which is usually performed through exposure or 
cognitive processing of thoughts related to the trauma.
Non-trauma-focused 
cognitive behavioural therapy
Non-TF-CBT Non-TF-CBT is a CBT programme that focuses on teaching skills for the 
reduction of anxiety. These treatments use procedures that directly target the 
person’s beliefs and behaviours rather than the discussions of specific traumas.
Cognitive therapy CT CT mainly uses cognitive restructuring training, which aims at examining 
youths’ automatic thoughts and core schemas and evaluating the accuracy and 
affective consequences of their views. They aim to teach youths to engage in 
‘rational’ thinking about themselves, the traumatic incident and the world.
Behavioural therapy BT BT uses some form of behavioural training, especially for exposure -based 
therapy and narrative therapy, to help youth reduce trauma-related symptoms. 
BT is based on principles of habituation.
Eye movement desensitisation 
and reprocessing
EMDR EMDR aims to help a person reprocess their memories of a traumatic event. 
The therapy involves bringing distressing trauma-related images, beliefs and 
bodily sensations to mind.
Psychodynamic therapy DYN Psychodynamic psychotherapy focuses on integrating the traumatic experience 
into the life experience of the individual as a whole. Childhood issues are often 
felt to be important.
Play therapy PT PT used techniques to engage participants in recreational activities to help 
them cope with their problems and fears.
Stress management SM SM mainly includes some form of relaxation or biofeedback
Supportive therapy ST ST is an unstructured therapy without specific psychological techniques that 
it helped people to ventilate their experiences and emotions and offering 
empathy, for example, supportive counselling, attention control, minimal 
contact, active listening, common factor control, non-specific control.
Control conditions
Treatment as usual TAU TAU is often described as ‘usual care’ or ‘usual community treatment’ in trials, 
which may include any components of psychotherapy or pharmacotherapy for 
PTSD. It is not considered to be structured intervention but may have some 
treatment effects.
Waitlist WL WL is a control condition in which the participants receive no active treatment 
during the study but are informed that they can receive one after the study 
period is over.
No treatment NT NT is a control condition in which the participants receive no active treatment 
during the study and in which they do not expect to receive such after the study 
is over.
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scales of QoL include Quality of Life Enjoyment and 
Satisfaction Questionnaire, Paediatric Quality of Life 
Inventory (QoL Child Report), the Quality of Life 
Inventory and others. The scales of functional im-
provement include the Children’s Global Assessment 
Scale, the Global Assessment Functioning and others. 
When scales of quality of life and functional improve-
ment are both reported in a trial, we will extract the 
data of quality of life.
Search strategy
We will identify relevant trials from systematic searches in 
the following electronic databases: PubMed, Cochrane, 
Embase, Web of Science, PsycINFO, Cumulative Index of 
Nursing and Allied Health, PILOTS and ProQuest Disser-
tations. The timeline will be from database inception to 
October 2017. An example of search strategy for PubMed is 
included in the online supplementary material. In addition, 
international trials registers, such as WHO’s trials portal, 
ClinicalTrials. gov and Australian New Zealand Clinical Trials 
Registry will be searched for ongoing trials. Furthermore, we 
will search the presentations at European Psychiatric Asso-
ciation, European College of Neuropsychopharmacology, 
American Psychological Association, American Psychiatric 
Association and European Society for Child and Adolescent 
Psychiatry congresses and hand search relevant key psychi-
atric, psychological and medical journals (including Behavior 
Therapy, Child Abuse and Neglect, Child Maltreatment, Journal 
of Counseling and Development, Counseling Outcome Research 
and Evaluation, Journal of Anxiety Disorders, Journal of Mental 
Health Counseling, Journal of Trauma Practice, Journal of Trau-
matic Stress, Journal of the American Academy of Child and Adoles-
cent Psychiatry, Journal of Consulting and Clinical Psychology, 
Behaviour research and therapy). The reference lists of included 
trials and reviews identified from initial searches will be 
scanned for more relevant studies. All relevant authors will 
be contacted to complement the incomplete data.
study selection and data extraction
Selection of trials
Two reviewers (YZ and LY) will independently identify 
potentially eligible studies from the titles and abstracts 
of records from the search strategies. Studies will be 
excluded if both reviewers consider that it does not meet 
eligibility criteria. Then, the full texts of these potentially 
eligible studies will be reviewed by the same criteria. The 
inter-rater reliability of the two reviewers will be calcu-
lated to detect their consistency. All disagreements will 
be discussed and resolved by a senior review author (PX 
or SEH). The references of relevant reviews and included 
trials will be checked by YZ and LY. Where multiple publi-
cations derive from a common dataset, we will select the 
trials in which the relevant outcomes we predefined in 
this protocol were reported completely. We will report the 
reasons for exclusion for each trial in the characteristics 
of excluded studies list. Finally, a flow chart will be used to 
present the process of trial screening in this meta-analysis.
Risk of bias assessment
Two reviewers (YZ and XZ) will independently assess 
the methodological quality of the included studies. 
According to the Cochrane Collaboration’s risk of bias 
V.2.0 tool,51 the risk of bias will be rated as ‘low risk’, ‘high 
risk’ or ‘some concerns’ in the following domains: (1) 
bias arising from the randomisation process; (2) bias due 
to deviations from intended interventions; (3) bias due 
to missing outcome data; (4) bias in measurement of the 
outcome; (5) bias in selection of the reported result and 
(6) overall bias. The inter-rater reliability of the two 
reviewers assessing the risk of bias will also be calculated. 
Table 2 Hierarchy of PTSD symptom severity measurement scales
Hierarchy PTSD symptom severity rating scales Abbreviation
1 UCLA Post-Traumatic Stress Disorder Reaction Index UCLA PTSD Index
2 Child PTSD Symptoms Scale CPSS
3 Clinician-Administered PTSD Scale/Clinician Administered PTSD Scale-Child and Adolescent 
Version
CAPS/CAPS-CA
4 Impact of Events Scale/The Children’s Revised Impact of Events Scale IES/CRIES
5 Parent Report of Post-traumatic Symptoms/Child Report of Post-traumatic Symptoms PROPS/CROPS
6 Kiddie-Schedule for Affective Disorders and Schizophrenia K-SADS
7 Trauma Symptom Checklist for Children TSCC
8 Post-Traumatic Cognitions Inventory/Child Post-traumatic Cognitions Inventory PTCI/CPTCI
9 Harvard Trauma Questionnaire HTQ
10 Post-traumatic Stress Scale PSS
11 Child Post-Traumatic Stress—Reaction Index CPTS-RI
12 The Preschool Age Psychiatric Assessment PAPA
13 Anxiety Disorders Interview Schedule ADIS
UCLA, University of California, Los Angeles.
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Any disagreements will be resolved by a senior review 
author (PX or SEH).
Data extraction
A standardised data extraction form will be used by two 
independent reviewers (YZ and XZ) to record the relevant 
parameters from the original paper, including study char-
acteristics (eg, title, first author, publication year, publi-
cation type, publication journal, location and sponsor), 
patient characteristics (eg, diagnostic criteria for PTSD, 
type of trauma, severity of PTSD symptoms, comorbidities 
and the number, mean age and gender of participants), 
intervention details (eg, type of psychotherapy, treat-
ment format, treatment setting, treatment duration, the 
number of sessions, follow-up duration and cointerven-
tions) and outcome measures (mean scores, number of 
participants and outcome raters (ie, self-rated or observer 
rated) for each predefined outcome). A table will be used 
to present the main characteristics of each study included 
in this review. The reliability of data extraction from the 
reviewers will also be assessed. Any disagreements will be 
resolved by a senior review author (PX or SEH).
statistical analysis
We will perform Bayesian network meta-analysis for each 
outcome with random-effects model in WinBUGS V.1.4.3. 
In addition, as a reference for relative outcomes of network 
meta-analyses, conventional pairwise meta-analyses will 
also be performed for each outcome with a random-ef-
fects model in Stata V.13.0. Standardised mean difference 
(SMD, Cohen’s d) will be used as a measure of effect size 
where outcome is measured on different scales. For dichot-
omous outcome (all-cause discontinuation), the effect sizes 
will be calculated as ORs. Statistical heterogeneity in each 
pairwise comparison will be assessed with the I² statistic 
and p value.52 When the mean values or SDs of continuous 
outcomes are missing, we will compute values by conversion 
from p values, t-values, CIs or SEs.53 Missing continuous 
outcome data will be analysed using completer data.
The pooled estimates of network meta-analysis will be 
obtained using the Markov Chains Monte Carlo method. 
Two Markov chains will be run simultaneously with different 
arbitrarily chosen initial values. Trace plots and the Brooks-
Gelman-Rubin statistic will be monitored to ensure conver-
gence.54 When the model is adequately convergent, the 
foregoing samples will be discarded. Then 100 000 subse-
quent simulations will be run as the posterior summaries. 
All results will be reported as effect sizes (SMD or OR) 
and their 95% credible intervals (CrI). We will assume a 
common heterogeneity parameter for each comparison 
and assess the global heterogeneity using the I2 statistic with 
‘gemtc’ package in R V.3.2.2. Furthermore, the inconsis-
tency between direct and indirect evidence will be evaluated, 
which will include the assessment of global inconsistency 
(by comparing the fit and parsimony of consistency and 
inconsistency models), local inconsistency (by calculating 
the difference among direct and indirect evidence in closed 
loops in the network)55 and the inconsistency calculated by 
node splitting method (by assessing the difference between 
direct and indirect estimates within a particular compar-
ison).56 Probability values will be summarised and reported 
as surface under the cumulative ranking curve to provide a 
hierarchy of the treatments.57
Subgroup analysis
Where possible, we will conduct network meta-regression 
of data on primary outcome to evaluate the influence 
of the following potential moderators: (1) age group; 
(2) sex ratio; (3) number of sessions; (4) sample size; 
(5) risk of bias; (6) trauma types (acute/single trauma 
vs chronic trauma); (7) diagnosis criteria (youth with a 
diagnosis vs with subsyndromal symptoms); (8) source 
of outcome measure (self-rated vs observer rated). If the 
data are insufficient to conduct subgroup analyses for 
some moderators, we will perform sensitivity analyses by 
omitting specific trials from the overall analysis.
Other analyses
Comparison-adjusted funnel plots and Egger’s test will be 
used for each outcome to examine whether there is domi-
nant publication bias exists in this network meta-anal-
ysis.56 In addition, we will evaluate the quality of evidence 
for primary outcome by using the Grading  of Recom-
mendations, Assessment, Development and Evaluations 
framework, which characterises the quality of a body of 
evidence on the basis of the study limitations, impreci-
sion, inconsistency, indirectness and publication bias for 
network estimates.58
dIsCussIOn
This systematic review and network meta-analysis will 
comprehensively evaluate the comparative efficacy and 
acceptability of psychological interventions for children 
and adolescents with PTSD. The results of this research 
will provide evidence to inform a hierarchy of compar-
ative efficacy at post-treatment, efficacy with regard 
to PTSD symptoms at follow-up, as well as in terms of 
acceptability (all-cause discontinuation), improvement 
of anxiety symptoms, improvement of depressive symp-
toms and quality of life and functional improvement. We 
expect that the findings could assist patients, clinicians 
and healthcare providers to make a better informed 
choice in treatment selection.
There are some limitations in this protocol. First, due 
to the fact that PTSD commonly co-occurs with other 
psychiatric comorbidities, we will not exclude trials in 
which patients with comorbidity were enrolled. This will 
enhance the generalisability of this study; however, it will 
also raise the risk of bias for outcomes. Further individual 
patient data meta-analysis will be helpful to investigate 
the influence of this factor. Second, some trials may tend 
to report their favourite outcomes. Although we have 
predefined the data selection criteria for each outcome, 
this selection bias could not be completely eliminated.
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